Clinical Trial Update: An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 open-label study to evaluate Tanruprubart (ANX005) in participants with Guillain-Barré syndrome, which is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Guillain-barré Syndrome

Drugs mentioned

• Tanruprubart (ANX005)

Snippet

Sponsor: Annexon, Inc. | Conditions: Guillain-Barre Syndrome | Phase 3 | Status: RECRUITING